Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain
Prostatype Genomics (”Prostatype Genomics” or ”the Company”) announces that the retrospective multicentre study in Spain with the Company’s gene test Prostatype®, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, has now been completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype® had been used as a decision basis at the time of diagnosis. Prostatype® was launched in Spain in 2023, and Prostatype Genomics now see good